65,437 trials
Perennial Allergic Rhinitis
Primary: The Number of Subjects Experiencing Nasal Mucosal Disorders, Septum Disorders, or Nasal Septum Perforations as Treatment Emergent Adverse Events (AEs; TEAE) — 3; 4; 2; 0…
Caries
Primary: Percentage (%) Change in Surface Microhardness (SMH) Following 21 Days of Twice Daily Treatment With the 1500 Ppm Fluoride + 5% CSP Dentifrice and With the 1500 Ppm…
Type 2 Diabetes Mellitus · Secondary Hypogonadism
Primary: Change in HbA1C — 0; 0; 0 Ratio
Constipation
Primary: Whole Gut Transit Time
Secondary Hypogonadism
Primary: Change From Baseline in Total Morning Testosterone at 26 Weeks — 280.9; 214.7 ng/dL
Otitis Media
Primary: Number of Participants With Procedural, Serious, and Device-Related Adverse Events — 0 participants
Atopic Dermatitis
Primary: Post Treatment Serum Cortisol Values Will be Compared. — 1 participants
Sexual Violence
Primary: Prosocial Intervening Behavior — 72.2; 81.1 percent score on a scale — p=.044
Induction of Labor
Primary: Time to the Second Stage of Labor — 18.2; 14.6 hours
Smoking
Primary: Self Reported 30 Day Smoking Quit Rate — 0 participants
Spinal Cord Injuries
Primary: Net Change of the Urinary Distress Inventory (UDI-6) — 10.4; 7.43 units on a scale
Healthy Subjects
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 4; 2; 4; 3 Participants
Healthy
Primary: Empagliflozin: Area Under the Curve for the Dosing Interval at Steady State (AUCτ,ss) — 4580.38; 4621.37 nmol*h/L
Multiple Myeloma
Primary: Clinical Response to Treatment — 81.5 percentage of participants
Advanced Cancer
Primary: Herth Hope Index — 37.79; 39.74; 39.06; 38.17 units on a scale — p=<0.05